Actively Recruiting

Phase Not Applicable
All Genders
NCT06104930

Plasma Extracellular Vesicles in Meningioma Patients

Led by University Hospital Heidelberg · Updated on 2026-03-10

60

Participants Needed

1

Research Sites

221 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

While surgical resection remains the primary treatment approach for symptomatic or growing meningiomas, radiotherapy represents an auspicious alternative in patients with meningiomas not safely amenable to surgery. Biopsies are often omitted in light of potential postoperative neurological deficits, resulting in a lack of histological grading and (molecular) risk stratification. In this prospective explorative biomarker study, extracellular vesicles in the bloodstream will be investigated in patients with macroscopic meningiomas to identify a biomarker for molecular risk stratification and disease monitoring.

CONDITIONS

Official Title

Plasma Extracellular Vesicles in Meningioma Patients

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed meningioma by histology or MRI/DOTATOC-PET CT
  • Macroscopic tumor visible on MRI suitable for radiotherapy
  • Indication for radiotherapy treatment
  • Completed wound healing after any surgical intervention
  • Age 18 years or older
  • Karnofsky Performance Score of 60% or higher
  • Provided written informed consent
  • Ability to understand the nature and consequences of the trial
  • Adequate contraception for women of childbearing potential
Not Eligible

You will not qualify if you...

  • History of other tumor diseases within the past 5 years
  • Previous cerebral radiotherapy
  • Receiving chemotherapy or immunotherapy at the same time
  • Inability to follow the study protocol (e.g., non-compliance)
  • Refusal to participate in the study
  • Participation in another clinical study or observation in a competing trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Hospital of Heidelberg, Radiation Oncology

Heidelberg, Germany, 69120

Actively Recruiting

Loading map...

Research Team

M

Max Deng, MD

CONTACT

A

Adriane Lentz-Hommertgen, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

BASIC_SCIENCE

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here